|
1
|
Clarke JD, Dashwood RH and Ho E:
Multi-targeted prevention of cancer by sulforaphane. Cancer Lett.
269:291–304. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Barcelo S, Gardiner JM, Gescher A and
Chipman JK: CYP2E1-mediated mechanism of anti-genotoxicity of the
broccoli constituent sulforaphane. Carcinogenesis. 17:277–282.
1996. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Langouët S, Furge LL, Kerriguy N, Nakamura
K, Guillouzo A and Guengerich FP: Inhibition of human cytochrome
P450 enzymes by 1,2-dithiole-3-thione, oltipraz and its
derivatives, and sulforaphane. Chem Res Toxicol. 13:245–252. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Heiss E, Herhaus C, Klimo K, Bartsch H and
Gerhäuser C: Nuclear factor kappa B is a molecular target for
sulforaphane-mediated anti-inflammatory mechanisms. J Biol Chem.
276:32008–32015. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Parnaud G, Li P, Cassar G, Rouimi P,
Tulliez J, Combaret L and Gamet-Payrastre L: Mechanism of
sulforaphane-induced cell cycle arrest and apoptosis in human colon
cancer cells. Nutr Cancer. 48:198–206. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Singh SV, Herman-Antosiewicz A, Singh AV,
Lew KL, Srivastava SK, Kamath R, Brown KD, Zhang L and Baskaran R:
Sulforaphane-induced G2/M phase cell cycle arrest
involves checkpoint kinase 2-mediated phosphorylation of cell
division cycle 25C. J Biol Chem. 279:25813–25822. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Herman-Antosiewicz A, Johnson DE and Singh
SV: Sulforaphane causes autophagy to inhibit release of cytochrome
c and apoptosis in human prostate cancer cells. Cancer Res.
66:5828–5835. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Choi S and Singh SV: Bax and Bak Are
required for apoptosis induction by sulforaphane, a cruciferous
vegetable-derived cancer chemopreventive agent. Cancer Res.
65:2035–2043. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Shankar S, Ganapathy S and Srivastava RK:
Sulforaphane enhances the therapeutic potential of TRAIL in
prostate cancer orthotopic model through regulation of apoptosis,
metastasis, and angiogenesis. Clin Cancer Res. 14:6855–6866. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Moon DO, Kim MO, Kang SH, Choi YH and Kim
GY: Sulforaphane suppresses TNF-alpha-mediated activation of
NF-kappaB and induces apoptosis through activation of reactive
oxygen species-dependent caspase-3. Cancer Lett. 274:132–142. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Edwards MC, Wong C and Elledge SJ: Human
cyclin K, a novel RNA polymerase II-associated cyclin possessing
both carboxy-terminal domain kinase and Cdk-activating kinase
activity. Mol Cell Biol. 18:4291–4300. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Fu TJ, Peng J, Lee G, Price DH and Flores
O: Cyclin K functions as a CDK9 regulatory subunit and participates
in RNA polymerase II transcription. J Biol Chem. 274:34527–34530.
1999. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Napolitano G, Majello B, Licciardo P,
Giordano A and Lania L: Transcriptional activity of positive
transcription elongation factor b kinase in vivo requires the
C-terminal domain of RNA polymerase II. Gene. 254:139–145. 2000.
View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Blazek D, Kohoutek J, Bartholomeeusen K,
Johansen E, Hulinkova P, Luo Z, Cimermancic P, Ule J and Peterlin
BM: The Cyclin K/Cdk12 complex maintains genomic stability via
regulation of expression of DNA damage response genes. Genes Dev.
25:2158–2172. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Zhou Z and Fu XD: Regulation of splicing
by SR proteins and SR protein-specific kinases. Chromosoma.
122:191–207. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Baldin V, Lukas J, Marcote MJ, Pagano M
and Draetta G: Cyclin D1 is a nuclear protein required for cell
cycle progression in G1. Genes Dev. 7:812–821. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Akiyama N, Sasaki H, Katoh O, Sato T,
Hirai H, Yazaki Y, Sugimura T and Terada M: Increment of the cyclin
D1 mRNA level in TPA-treated three human myeloid leukemia cell
lines: HEL, CMK and HL-60 cells. Biochem Biophys Res Commun.
195:1041–1049. 1993. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Tiemann K, Alluin JV, Honegger A, Chomchan
P, Gaur S, Yun Y, Forman SJ, Rossi JJ and Chen RW: Small
interfering RNAs targeting cyclin D1 and cyclin D2 enhance the
cytotoxicity of chemotherapeutic agents in mantle cell lymphoma
cell lines. Leuk Lymphoma. 52:2148–2154. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Danos AM, Liao Y, Li X and Du W:
Functional inactivation of Rb sensitizes cancer cells to TSC2
inactivation induced cell death. Cancer Lett. 328:36–43. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Pines J and Hunter T: Human cyclin A is
adenovirus E1A-associated protein p60 and behaves differently from
cyclin B. Nature. 346:760–763. 1990. View
Article : Google Scholar : PubMed/NCBI
|
|
21
|
Innocente SA, Abrahamson JL, Cogswell JP
and Lee JM: p53 regulates a G2 checkpoint through cyclin B1. Proc
Natl Acad Sci USA. 96:2147–2152. 1999. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Holloway SL, Glotzer M, King RW and Murray
AW: Anaphase is initiated by proteolysis rather than by the
inactivation of maturation-promoting factor. Cell. 73:1393–1402.
1993. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Wang Z, Fan M, Candas D, Zhang TQ, Qin L,
Eldridge A, Wachsmann-Hogiu S, Ahmed KM, Chromy BA, Nantajit D, et
al: Cyclin B1/Cdk1 coordinates mitochondrial respiration for
cell-cycle G2/M progression. Dev Cell. 29:217–232. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Sugrue MM, Shin DY, Lee SW and Aaronson
SA: Wild-type p53 triggers a rapid senescence program in human
tumor cells lacking functional p53. Proc Natl Acad Sci USA.
94:9648–9653. 1997. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Livak KJ and Schmittgen TD: Analysis of
relative gene expression data using real-time quantitative PCR and
the 2ΔΔCT method. Methods.
25:402–408. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Lánczky A, Nagy Á, Bottai G, Munkácsy G,
Szabó A, Santarpia L and Győrffy B: miRpower: A web-tool to
validate survival-associated miRNAs utilizing expression data from
2178 breast cancer patients. Breast Cancer Res Treat. 160:439–446.
2016. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Siegel RL, Miller KD and Jemal A: Cancer
statistics, 2017. CA Cancer J Clin. 67:7–30. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Zhang Y and Callaway EC: High cellular
accumulation of sulphoraphane, a dietary anticarcinogen, is
followed by rapid transporter-mediated export as a glutathione
conjugate. Biochem J. 364:301–307. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Hamsa TP, Thejass P and Kuttan G:
Induction of apoptosis by sulforaphane in highly metastatic B16F-10
melanoma cells. Drug Chem Toxicol. 34:332–340. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Zhang Z, Li C, Shang L, Zhang Y, Zou R,
Zhan Y and Bi B: Sulforaphane induces apoptosis and inhibits
invasion in U251MG glioblastoma cells. Springerplus. 5:2352016.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Ferreira de Oliveira JM, Remédios C,
Oliveira H, Pinto P, Pinho F, Pinho S, Costa M and Santos C:
Sulforaphane induces DNA damage and mitotic abnormalities in human
osteosarcoma MG-63 cells: Correlation with cell cycle arrest and
apoptosis. Nutr Cancer. 66:325–334. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Ferreira de Oliveira JM, Costa M, Pedrosa
T, Pinto P, Remédios C, Oliveira H, Pimentel F, Almeida L and
Santos C: Sulforaphane induces oxidative stress and death by
p53-independent mechanism: Implication of impaired glutathione
recycling. PLoS One. 9:e929802014. View Article : Google Scholar : PubMed/NCBI
|
|
33
|
Chen HH and Kuo MT: Role of glutathione in
the regulation of cisplatin resistance in cancer chemotherapy. Met
Based Drugs. 2010(pii): 4309392010.PubMed/NCBI
|
|
34
|
Backos DS, Franklin CC and Reigan P: The
role of glutathione in brain tumor drug resistance. Biochem
Pharmacol. 83:1005–1012. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Cooper WA, Kohonen-Corish MR, McCaughan B,
Kennedy C, Sutherland RL and Lee CS: Expression and prognostic
significance of cyclin B1 and cyclin A in non-small cell lung
cancer. Histopathology. 55:28–36. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Aaltonen K, Amini RM, Heikkilä P,
Aittomäki K, Tamminen A, Nevanlinna H and Blomqvist C: High cyclin
B1 expression is associated with poor survival in breast cancer. Br
J Cancer. 100:1055–1060. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
37
|
Begnami MD, Fregnani JH, Nonogaki S and
Soares FA: Evaluation of cell cycle protein expression in gastric
cancer: Cyclin B1 expression and its prognostic implication. Hum
Pathol. 41:1120–1127. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Kedinger V, Meulle A, Zounib O, Bonnet ME,
Gossart JB, Benoit E, Messmer M, Shankaranarayanan P, Behr JP,
Erbacher P, et al: Sticky siRNAs targeting survivin and cyclin B1
exert an antitumoral effect on melanoma subcutaneous xenografts and
lung metastases. BMC Cancer. 13:3382013. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Cheng YM, Tsai CC and Hsu YC:
Sulforaphane, a dietary isothiocyanate, induces G2/M
arrest in cervical cancer cells through cyclinB1 downregulation and
GADD45β/CDC2 association. Int J Mol Sci. 17(pii): E15302016.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Korenaga D, Takesue F, Yasuda M, Honda M,
Nozoe T and Inutsuka S: The relationship between cyclin B1
overexpression and lymph node metastasis in human colorectal
cancer. Surgery. 131 Suppl 1:S114–S120. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Fang Y, Liang X, Jiang W, Li J, Xu J and
Cai X: Cyclin B1 suppresses colorectal cancer invasion and
metastasis by regulating E-cadherin. PLoS One. 10:e01268752015.
View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Wang DX, Zou YJ, Zhuang XB, Chen SX, Lin
Y, Li WL, Lin JJ and Lin ZQ: Sulforaphane suppresses EMT and
metastasis in human lung cancer through miR-616-5p-mediated
GSK3β/β-catenin signaling pathways. Acta Pharmacol Sin. 38:241–251.
2017. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Żuryń A, Litwiniec A, Safiejko-Mroczka B,
Klimaszewska-Wiśniewska A, Gagat M, Krajewski A, Gackowska L and
Grzanka D: The effect of sulforaphane on the cell cycle, apoptosis
and expression of cyclin D1 and p21 in the A549 non-small cell lung
cancer cell line. Int J Oncol. 48:2521–2533. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Hagemann JH, Thomasova D, Mulay SR and
Anders HJ: Nrf2 signalling promotes ex vivo tubular epithelial cell
survival and regeneration via murine double minute (MDM)-2. Nephrol
Dial Transplant. 28:2028–2037. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Yang P, Chen W, Li X, Eilers G, He Q, Liu
L, Wu Y, Wu Y, Yu W, Fletcher JA and Ou WB: Downregulation of
cyclin D1 sensitizes cancer cells to MDM2 antagonist Nutlin-3.
Oncotarget. 7:32652–32663. 2016.PubMed/NCBI
|
|
46
|
Li L, Cui D, Zheng SJ, Lou H and Tang J:
Regulation of Actinomycin D induced upregulation of Mdm2 in H1299
cells. DNA Repair. 11:112–119. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Sansó M and Fisher RP: Pause, play,
repeat: CDKs push RNAP II's buttons. Transcription. 4:146–152.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Bartkowiak B, Liu P, Phatnani HP, Fuda NJ,
Cooper JJ, Price DH, Adelman K, Lis JT and Greenleaf AL: CDK12 is a
transcription elongation-associated CTD kinase, the metazoan
ortholog of yeast Ctk1. Genes Dev. 24:2303–2316. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Bell D, Berchuck A, Birrer M, Chien J,
Cramer D, Dao F, Dhir R, DiSaia P, Gabra H, Glenn P, et al:
Integrated genomic analyses of ovarian carcinoma. Nature.
474:609–615. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
50
|
Ekumi KM, Paculova H, Lenasi T,
Pospichalova V, Bösken CA, Rybarikova J, Bryja V, Geyer M, Blazek D
and Barboric M: Ovarian carcinoma CDK12 mutations misregulate
expression of DNA repair genes via deficient formation and function
of the Cdk12/CycK complex. Nucleic Acids Res. 43:2575–2589. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Carter SL, Cibulskis K, Helman E, McKenna
A, Shen H, Zack T, Laird PW, Onofrio RC, Winckler W, Weir BA, et
al: Absolute quantification of somatic DNA alterations in human
cancer. Nat Biotechnol. 30:413–421. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
52
|
Mertins P, Mani DR, Ruggles KV, Gillette
MA, Clauser KR, Wang P, Wang X, Qiao JW, Cao S, Petralia F, et al:
Proteogenomics connects somatic mutations to signalling in breast
cancer. Nature. 534:55–62. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
53
|
O'Connell BC, Adamson B, Lydeard JR, Sowa
ME, Ciccia A, Bredemeyer AL, Schlabach M, Gygi SP, Elledge SJ and
Harper JW: A genome-wide camptothecin sensitivity screen identifies
a mammalian MMS22L-NFKBIL2 complex required for genomic stability.
Mol Cell. 40:645–657. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
54
|
Joshi PM, Sutor SL, Huntoon CJ and Karnitz
LM: Ovarian cancer-associated mutations disable catalytic activity
of CDK12, a kinase that promotes homologous recombination repair
and resistance to cisplatin and poly(ADP-ribose) polymerase
inhibitors. J Biol Chem. 289:9247–9253. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
55
|
Kim HE, Kim DG, Lee KJ, Son JG, Song MY,
Park YM, Kim JJ, Cho SW, Chi SG, Cheong HS, et al: Frequent
amplification of CENPF, GMNN and CDK13 genes in hepatocellular
carcinomas. PLoS One. 7:e432232012. View Article : Google Scholar : PubMed/NCBI
|
|
56
|
Schecher S, Walter B, Falkenstein M,
Macher-Goeppinger S, Stenzel P, Krümpelmann K, Hadaschik B, Perner
S, Kristiansen G, Duensing S, et al: Cyclin K dependent regulation
of Aurora B affects apoptosis and proliferation by induction of
mitotic catastrophe in prostate cancer: Cyclin K in prostate
cancer. Int J Cancer. 141:1643–1653. 2017. View Article : Google Scholar : PubMed/NCBI
|
|
57
|
Johannes JW, Denz CR, Su N, Wu A,
Impastato AC, Mlynarski S, Varnes JG, Prince DB, Cidado J, Gao N,
et al: Structure-based design of selective noncovalent CDK12
inhibitors. ChemMedChem. 13:231–235. 2018. View Article : Google Scholar : PubMed/NCBI
|
|
58
|
Zhang T, Kwiatkowski N, Olson CM,
Dixon-Clarke SE, Abraham BJ, Greifenberg AK, Ficarro SB, Elkins JM,
Liang Y, Hannett NM, et al: Covalent targeting of remote cysteine
residues to develop CDK12 and CDK13 inhibitors. Nat Chem Biol.
12:876–884. 2016. View Article : Google Scholar : PubMed/NCBI
|
